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Abstract: Genetic mutations and aberrant epigenetic alterations are the triggers for carcinogenesis.
The emergence of the drugs targeting epigenetic aberrations has provided a better outlook for
cancer treatment. Histone deacetylases (HDACs) are epigenetic modifiers playing critical roles in
numerous key biological functions. Inappropriate expression of HDACs and dysregulation of PI3K
signaling pathway are common aberrations observed in human diseases, particularly in cancers.
Histone deacetylase inhibitors (HDACIs) are a class of epigenetic small-molecular therapeutics
exhibiting promising applications in the treatment of hematological and solid malignancies, and in
non-neoplastic diseases. Although HDACIs as single agents exhibit synergy by inhibiting HDAC and
the PI3K pathway, resistance to HDACIs is frequently encountered due to activation of compensatory
survival pathway. Targeted simultaneous inhibition of both HDACs and PI3Ks with their respective
inhibitors in combination displayed synergistic therapeutic efficacy and encouraged the development
of a single HDAC-PI3K hybrid molecule via polypharmacology strategy. This review provides an
overview of HDACs and the evolution of HDACs-based epigenetic therapeutic approaches targeting
the PI3K pathway.
Keywords: epigenetics; histone deacetylase; histone deacetylase inhibitors; phosphatidylinositol
kinase; HDAC-PI3K hybrid molecule; CUDC-907

1. Introduction
Phosphatidylinositol 3-kinases (PI3Ks) are a family of intracellular signaling lipid kinases that
regulate a wide array of cellular processes essentially in all normal tissues. Members of the PI3Ks
family are categorized into three distinct classes (class I-III) based on their structure, expression,
regulation, and substrate specificity. Class I PI3K family includes well-known four different PI3Ks
named PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ and are implicated in remarkably diverse pathways [1,2].
An extensive amount of research knowledge related to the PI3Ks reveals that they transduce a host of
cellular signals and regulate a wide range of essential cellular processes and physiological functions,
including cell growth, proliferation, differentiation, survival, migration, death, and metabolism [1–3].
Naturally, the PI3K pathway is highly regulated by multiple mechanisms, often involving crosstalk
with other signaling pathways in various physiological and pathophysiological situations. Importantly,
the major outcome of intense investigations of PI3K signaling is the realization that aberrant activation
of signaling is strongly linked to human diseases particularly in various types of cancers [4–7]. In recent
years, a number of PI3K pathway inhibitors have been developed using the PI3K pathway as a drug
target in human cancers, and many of them are being used in preclinical and clinical trials. However,
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clinical trials with early versions of PI3K inhibitors (PI3KIs) used as single-target drugs in monotherapy
have exhibited limited efficacy, due to compensatory or concurrent activation of other survival and
growth-related signaling pathways [8,9].
To overcome the limitations of a single-target approach, alternative strategies are being developed
to block tumor growth and progression. Among these, inhibition of histone deacetylase (HDAC) activity
appears to be a promising approach. By inducing growth-inhibitory cellular effects and by regulating
both histones and non-histones substrates via regulating signaling pathways, histone deacetylase
inhibitors (HDACIs) exhibit the potential to induce synergistic antitumor activity [10–13]. Moreover,
the latest polypharmacology approach that is designed to overcome the limitations of a single-target
approach appears to have a superior therapeutic effect with an affiliated reduction in adverse reactions
and diminished potential drug resistance. Specifically, the epigenetic polypharmacology approach,
using a dual-acting HDAC and PI3K inhibitor, by incorporating HDACI functionality into a PI3KI
pharmacophore, is capable of potent anticancer activity [14–16]. Simultaneous inhibition of HDACs
and PI3K activity by the dual HDAC and PI3K inhibitor can disrupt the oncogenic signaling network
in cancer cells [14–16]. This review will focus on the role of HDACs and PI3K signaling in malignancy.
Extend this information to understand the effectiveness of polypharmacology-based strategy in
blocking oncogenic signaling networks.
2. Phosphatidylinositol 3-Kinases (PI3Ks)
2.1. Class I Phospatidylinositol 3-Kinases
Class I PI3Ks are involved in diverse pathways activated by an array of signals including growth
factors, mitogenic factors, and hormones [1,2]. Class I PI3Ks are different in their tissue distribution and
functions. While PI3Kα and PI3Kβ isoforms are ubiquitously expressed, PI3Kγ and PI3Kδ isoforms are
enriched in hematopoietic cells such as leukocytes [17]. Class I PI3Ks are further subdivided into class
IA (PI3Kα, PI3Kβ, and PI3Kδ) and class IB (PI3Kγ) and are heterodimers composed of a regulatory
subunit (p85 or p101 family) and a catalytic subunit (p110α, p110β, p110γ or p110δ). All four class
I catalytic subunits, p110α, p110β, p110γ, and p110δ are encoded by PIK3CA, PIK3CB, PIK3CG,
and PIK3CD genes, respectively. The p85 regulatory subunit consists of p85α (p85α, p55α, or p50α
splice variants), p85β and p85γ and is encoded by PIK3R1, PIk34R2, and PIKR3 genes, respectively.
The catalytic subunits p110α, p110β, and p110δ associate with regulatory subunit p85 to form class IA
PI3Kα, PI3Kβ, and PI3Kδ. The catalytic subunit p110γ and regulatory subunit p101 together form
class IB PI3Kγ. All four class I PI3Ks catalyze the conversion of phosphatidylinositol 4,5-biphosphate
[PI(4,5)P2 ] to phosphatidylinositol 3,4,5-triphosphate [PI(3,4,5,)P3 ]. PI(3,4,5,)P3 (PIP3 ) is a second
messenger involved in the activation of a number of downstream molecules of the PI3K signaling
pathway [1,2,18].
PI3Ks transduce a host of cellular signals and regulate a wide range of essential cellular
processes and physiological functions, including cell growth, proliferation, differentiation, survival,
migration, death, and metabolism [1–3]. Obviously, the PI3K pathway is highly regulated by multiple
mechanisms, often involving crosstalk with other signaling pathways in various physiological and
pathophysiological situations. Considering that the PI3K signaling is fundamental to normal cellular
processes and physiological functions, glitches in the regulation of the PI3K pathway can lead to the
pathogenesis of diseases. Overwhelming information indicates aberrant activation of the PI3K signaling
is strongly linked to human cancers [4–7]. Non-cancerous neurological disorders [19,20], cardiovascular
diseases [21–23], diabetes [24], immune disorders [17], and CLOVES syndrome characterized by
localized tissue outgrowths [25] also share a common etiology with oncogenesis.
Abnormal mutational activation or amplification of the PIK3CA gene encoding p110α catalytic
subunit of PI3Kα is the commonly observed event that is associated with a dysfunctional PI3K signaling
cascade in different human solid and hematological malignancies [4–7]. The PI3K pathway is also
dysregulated through other mechanisms including loss or inactivation of phosphatase and tensin
homolog on chromosome 10 (PTEN), a tumor suppressor, and upregulation of tyrosine kinase growth
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2.3. Phosphatidylinositol 3-Kinase Inhibitors
PI3KIs are subdivided into pan-PI3K inhibitors, isoform-specific PI3K inhibitors, dual PI3K/mTOR
inhibitors, mTOR, and Akt inhibitors [8,9,42]. Many of the PI3KIs are being used in preclinical and
clinical trials to treat cancers. The pan-PI3KIs such as pictilisib (Taselisib, GDC-0941), apitolisib
(GDC-0980), and buparlisb (BKM120) that target all class I isoforms exhibit similar efficacy. Since
PIK3CA is frequently mutated in solid tumors, isoform-specific PI3KIs such as alpelisib (BYL719) and
taselisib (GDC0032) that selectively target the PIK3CA protein product p100α are under preclinical and
clinical testing. On the other hand, B cell signaling is upregulated in chronic lymphocytic leukemia
through the hyperactivation of the PI3K pathway due to increased expression of PIK3CD protein
product p110δ in hematopoietic cells and lymphoid tissue. Idelalisib, a specific inhibitor for p110δ,
is the first PI3KI approved for the treatment of relapsed chronic lymphocytic leukemia in combination
with CD-20 antibody rituximab [37]. However, clinical trials with early versions of PI3KIs used as
single-target drugs in monotherapy have limited efficacy potentially due to compensatory or concurrent
activation of other survival and growth-related signaling pathways [8,9]. Different and alternative
strategies are being developed to block tumor growth and progression to overcome the limitations
of a single target approach. Among these, the latest polypharmacology approach that is designed to
overcome the limitations of single-target therapy appears to have a superior therapeutic effect along
with reduced adverse reactions and diminished potential drug resistance. Specifically, the epigenetic
polypharmacology approach which uses a dual-acting HDAC and PI3K inhibition by incorporating
HDAC inhibitor functionality into a PI3K inhibitor pharmacophore is capable of potent anticancer
activity by disrupting the oncogenic signaling network through simultaneous inhibition of HDACs
and PI3K in cancer cells [15,16].
3. Histone Deacetylases (HDACs)
HDACs are a family of enzymes that play crucial roles in a number of biological processes
essentially through silencing gene transcription. Gene expression is regulated by the contrasting
action of HDACs and histone acetyltransferases (HATs). The HATs mediate the acetylation of histones
promoting gene transcription, whereas HDACs suppress gene expression by deacetylating histones.
Besides histones, functions of several nonhistone proteins that are essential for cell proliferation,
differentiation, and apoptosis are regulated by acetylation/deacetylation.
3.1. Role of HDACs in Epigenetic Alterations
Apart from genetic mutations, alterations in epigenetic regulations are the main trigger for cancer
initiation, progression, and metastasis [11]. Chromatin is a dynamic structure subject to remodeling
through reversible epigenetic alterations in response to environmental cues. The architecture of
chromatin is subject to dynamic remodeling from a highly condensed transcriptionally repressive
state to a more relaxed transcriptionally permissible state in response to external and internal cues.
Thus, permitting accessibility of DNA to the transcriptional machinery. Such chromatin remodeling
is facilitated by epigenetic factors through various covalent posttranslational modifications (PTMs)
to the N-terminal histone tails, including acetylation, methylation, phosphorylation, ubiquitination,
and ADP-ribosylation. Among these epigenetic histone modifications, acetylation of histones plays
a crucial role in the epigenetic regulation of gene expression. Histone acetyltransferases (HATs)
and histone deacetylases (HDACs) represent two enzyme families that are crucial to epigenetic
regulation of gene expression. Acetylation of lysine ε- amino group of lysine side-chain in the
N-terminal tails of core histones (H2A, H2B, H3, and H4) is a reversible dynamic PTM regulated by
contrasting activities of HATs and HDACs [10–13]. Transfer of acetyl group to the lysine residues of
histones by HATs neutralizes their positive charges causing decondensed chromatin structure that is
accessible to transcriptional activation [43]. Additionally, multiple specific sites are acetylated on core
histones. These sites are recognized by bromodomain components found in certain proteins that are
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part of the chromatin-remodeling coactivator complexes involved in transcriptional activation [44].
In contrast, HDACs stimulate condensed and transcriptionally repressed chromatin structure by
deacetylating histones and are associated with corepressor complexes that takes part in transcriptional
suppression [10–13,45–49]. Besides acetylation, the lysine side chain of histones is a target of other PTMs
such as methylation, sumoylation, and ubiquitination [50–57]. However, these PTMs are mutually
exclusive on the same lysine residue, promoting a great potential for cross-regulation. Crosstalk
between these different PTMs at independent sites of histone forms a ”histone code” that is translated
to a specific biological outcome crucial to normal development, and disease pathogenesis [10,12,51–57].
Acetylation of lysine is a major PTM modification of histones and crossregulation between
acetylation and another PTM is crucial in modulating chromatin-based transcriptional control [50–57].
It is now recognized that thousands of human proteins are subject to reversible acetylation and
deacetylation [47,51,58]. Enrichment of acetylated proteins by immunoprecipitation with anti-acetyllysine antibodies, combined with high-resolution mass spectrometry-based proteomics, reveals
lysine acetylation is a widespread and important epigenetic PTM that affects histones and some
nuclear proteins, along with thousands of other human proteins [59,60]. Some of the acetylated
nonhistone proteins include transcription factors, various other nuclear regulators, and cytoplasmic
proteins, suggesting that lysine acetylation is not only crucial to the nuclear functions, but also
essential for regulating various cytoplasmic processes, including cytoskeletal dynamics, energy
metabolism, endocytosis, and signal transduction [47,51,52,61]. Moreover, several acetylated
nonhistone proteins are key factors in different signaling pathways. In some nonhistone proteins, lysine
acetylation occurs at multiple sites and crosstalk with phosphorylation, methylation, ubiquitination,
and other PTMs, leading to a code-like multisite modification program that is crucial for the control
of cellular signaling specific to a particular scenario. Considering that histones are not the only
proteins that are subject to reversible acetylation and deacetylation, it is conceivable that HATs,
HDACs, and bromodomains, the epigenetic players that add, erase, and read the acetyl group,
respectively, have a broader impact on signaling pathways. Accordingly, different HATs and HDACs
are now referred to as histone/lysine acetyltransferases (HATs/KATs) and histone deacetylase/lysine
deacetylases (HDACs/KDACs), respectively. These enzymes play a critical role in nonhistone protein
acetylation regulating signaling events essential for a range of cellular processes and physiological
and pathophysiological functions [62–64]. Epigenetic-driven alterations in lysine acetylation due to
dysregulated activities of several HATs/KATs, HDACs/KDACs, and bromodomain-containing proteins
have been linked to various diseases, notably in cancer, but also in cardiovascular disease, neurological
and immunological disorders [38–41,60,64–67]. A variety of HATs/KATs, HDACs/KDACs, and
bromodomain inhibitors have been developed, studied, and used as anticancer agents in clinical trials.
3.2. Types of HDACs
Enzymatic deacetylation was first detected in 1977 when Friend erythroleukemic cells (FEC) were
treated with n-butyrate [68]. Butyrate stimulated differentiation of FEC into hemoglobin-synthesizing
normal-like cells. This phenotypic change was linked to histone hyperacetylation, indicating the
presence of HDAC, and butyrate is recognized as HDACI. There are 18 different mammalian HDACs
that have been identified. HDACs are classified into four classes I, II, III, and IV [6,10,12,45]. Class I, II,
and IV are referred to as classical HDACs and class III enzymes are known as sirtuins. Class I, II, and IV
HDACs are dependent on Zn2+ for the deacetylase activity. Class I HDACs include HDAC1, HDAC2,
HDAC3, and HDAC8 that have sequence similarity to yeast counterpart RPD3. Class II HDACs are
related to yeast enzyme HDAI and are divided into subclasses IIa and IIb. The IIa includes HDAC4,
HDAC5 HDAC7, and HDAC9, whereas IIb includes HDAC6 and HDAC10. Class IV consists of only
HDAC11. Class III includes seven NAD+ -dependent sirtuins that are related to yeast counterpart Sir2.
HDACs have an important role in cytoplasmic functions besides their epigenetic functions
regulating gene expression. A number of cytoplasmic nonhistone proteins are acetylated by HDACs.
These proteins include transcription factors, transcription regulators, DNA repair enzymes, chaperone
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proteins, signal transduction mediators, cytoskeletal proteins, and inflammation mediators [12,13,69–71].
Accordingly, histone deacetylases/lysine deacetylases (HDACs/KDACs) are directly or indirectly
involved in several cellular functions such as gene expression, signaling pathways, protein stability,
protein-protein interaction, eventually affecting cell proliferation, growth, differentiation, apoptosis,
migration, and angiogenesis [12,13,69–71]. Moreover, altered expression of HDACs has been observed
in many cancerous and noncancerous diseases, particularly in cancer, advocating HDACs are important
therapeutic targets for anticancer therapies [72–74]. Therefore, the development of HDAC inhibitors is
essential to the therapeutic intervention of epigenetic diseases, cancer in particular.
4. Histone Deacetylase Inhibitors (HDACIs)
The cancer cells harbor the epigenetic abnormalities required for oncogenesis by altering the
epigenetic landscape of chromatin. Especially acetylation, one of the predominant modifications in
epigenetics, serves as a key regulatory mechanism for gene expression. The global dysregulation
of epigenetic histone acetylation modifications results in altered gene expression contributing to
the establishment of the disease state. Aberrant epigenetic alterations are the important drivers
in cancer pathogenesis often due to the silencing of tumor suppressor genes or overexpression of
oncogenes. Moreover, the cancer cells with a unique portfolio of epigenetic changes are different
from their normal counterparts. Accumulation of these altered epigenetic changes allows cancer
cells to solidify their exclusive phenotype through dysregulated gene expression changes [75–77].
Furthermore, the accumulation of altered epigenetic changes can also promote resistance to therapy
through the acquisition of pro-survival signaling [75,78]. The epigenetic histone acetylation alterations
induced by aberrant expression of HDACs can be reversed by pharmacological inhibition of HDACs
with HDACIs. Although HDACIs affect gene expression on a global level, their actions are specific
to the malignant phenotype and have been recognized that only about 8–20% of genes are affected
by HDACIs [79]. Additionally, HDACIs also indirectly affect gene expression by inhibiting HDACs
interactions with nonhistones.
The HDACIs are a class of small-molecules that inhibit the activity of Zn2+ -dependent classical
HDACs (class I, II, and class IV HDACs) and promote acetylation of histone and nonhistone protein
substrates. Originally, HDACIs were known for their varied cellular effects on cancer cells, such as
inhibiting cell proliferation and stimulating differentiation or apoptosis, advocating their usefulness
in anticancer drug discovery, and development [80,81]. Now, it is recognized HDACIs induce an
array of cellular effects [69,82,83]. They stimulate cell cycle arrest by upregulating p21Cip1 and
downregulating cyclins [69,84,85]. They also do the following: 1) Induce intrinsic and extrinsic
apoptosis pathways causing apoptosis [75,86,87]. 2) Induce autophagy [88]. 3) Promote anti-angiogenic
effect by altering Hif-1α function and downregulation of VEGF [89]. 4) Alter expression of nonhistone
proteins including transcription factors and regulators, inflammation/immune response mediators,
chaperones, DNA repair enzymes, and structural proteins [69,82,83,90]. These features of HDACIs
are exploited as promising anticancer epi-drugs and several HDACIs have entered clinical trials in
both hematologic and solid tumors [70,72–75,81–83,90]. As such, HDACIs are investigated mainly
as anticancer epi-drugs, even though HDAC enzymes also play a crucial role in other diseases
such as cardiovascular disease [91], neurological disorders [92], immunological processes and viral
infections [93], and other disorders [94].
4.1. Types of Histone Deacetylase Inhibitors (HDACIs)
Several HDACIs have been either isolated from natural sources or synthesized with differing
efficacy, potency, and pharmacokinetics [81,95]. The active site of Zn2+ -dependent HDACs consists
of a tubular pocket and a Zn2+ ion at the bottom of the pocket. The canonical pharmacophore
of the HDACIs is composed of three different parts. A cap structure (CAP) that interacts with
the rim of the tubular catalytic pocket of HDACs, a zinc ion binding group (ZBG), and a linker
spanning the length of the tubular pocket responsible for connecting the cap and the ZBG [12,13,96,97].
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Based on their Zn2+ -binding structure, HDACIs are classified into different classes. These include
hydroxamates, carboxylic acids, benzamides, and cyclic peptides, with differing potency, selectivity,
and toxicity [48,69,98]. Hydroximic acid based HDACIs include trichostatin A (TSA), vorinostat
(SAHA, suberoylanilide hydroxamic acid), panobinostat, belinostat, and several others. While TSA is
used only in laboratory studies because of its toxicity, vorinostat, panobinostat, belinostat, and several
others are approved for hematologic malignancies. Most of the hydroximic acid-based HDACIs are
pan-HDACIs. The carboxylic acid type of HDACIs includes short-chain fatty acids such as butyric
acid, phenylbutyrate, and valproic acid, which are weak inhibitors of HDAC class I and II. Butyrate
and phenylbutyrate acids are in several phase II and phase I trials, respectively. Valproic acid is
approved for epilepsy, bipolar disorders, and migraine. Among the benzamides, entinostat and
chidamide (HBI-8000) are HDAC class I inhibitors. Entinostat is in phase II trials for several different
hematologic and solid cancers. The cyclic tetrapeptides include the bicyclic depsipeptide romidepsin
(FK228, FR901228). It is an HDAC class I inhibitor that has been approved for treating cutaneous
T-cell lymphoma.
Most HDACIs are considered pan-inhibitors because they display a similar mechanism of action
on different classical HDACs except for class IIa HDACs. HDACIs bind to the zinc atom in the catalytic
pocket in a non-competitive manner but lacks selectivity. Thus, it is difficult to discern which classical
HDAC enzyme inhibition is responsible for the therapeutic or toxic effects observed in clinical trials.
To achieve desirable clinical outcomes, it would be appropriate to know which HDAC is contributing
to the pathogenesis so that HDAC-specific inhibitors can be developed in the future.
4.2. Histone Deacetylase Inhibitors in Clinical Trials
The early drugs like butyrate targeting HDACs are used based on phenotypic effects in cancer
models without knowing the specific targets. The observations that HDACIs exhibit varied cellular
effects on cancer cells such as inhibiting cell proliferation and stimulating differentiation or apoptosis,
point to their usefulness for anticancer drug discovery and development [80]. During the past ten
plus years, several promising HDACIs have surfaced as effective anticancer epi-drugs. Because of the
transient and reversible nature of epigenetic modifications and also based on their antiproliferative
and proapoptotic effects in cancer cells, several HDACIs are approved for cancer treatment by the
United States Food and Drug Administration (US FDA) [72–74,99]. Vorinostat, also (suberoylanilide
hydroxamic acid, SAHA), a hydroxamic acid, is the first pan-HDACI approved in 2006 for the
treatment of rare refractory cutaneous T-cell lymphoma (CTCL). Romidepsin (FK-288, FR901228, cyclic
depsipeptide), a natural prodrug having inhibitory activity against class I HDACs, is approved in
2009 for the treatment of rare refractory CTCL. Belinostat (PXD101), and panobinostat (LBH589) are
two other approved hydroxamate-containing pan-HDAC inhibitors. Belinostat is approved for the
treatment of peripheral T-cell lymphoma in 2014 and panobinostat for the treatment of refractory
multiple myeloma in 2015 [99]. Benzamide-based HDACI chidamide (HBI-8000) which inhibits
HDAC1, 2, 3 and 10 has been approved for the treatment of refractory peripheral T-cell lymphoma in
China [72–74,99]. Class I-selective benzamide containing entinostat and mocetinostat are in clinical
trials for several solid tumors. Even though the HDAC-specific epi-drugs display potent anticancer
activities on hematological malignancies, they exhibit limited effectiveness in supporting persistent
suppression of solid tumors in monotherapies [100–102]. The single epi-drug therapeutic strategy
is frequently ineffective in providing enduring tumor suppression. One of the main reasons for
ineffectiveness is, cancer cells can evade drug-induced effects by eliciting other compensatory survival
pathways due to the emergence of pharmacological resistance. Interestingly, HDACIs also exhibit
anticancer effect by disrupting pro-survival signaling through epigenetic drug-induced sensitization
mechanisms [75].
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4.3. Disruption of Pro-Survival Signaling by HDACIs
Epigenetic inhibitors can disrupt pro-survival signaling in cancers that have developed resistance
to therapy. During oncogenesis, epigenetic alterations can dysregulate the expression of certain
proteins such as growth factor receptors or proteins associated with apoptosis that provide survival
advantage causing resistance to therapy [75,103]. Increased expression of growth factor receptors
in cancer cells can allow them to become resistant to therapy by over-activating the downstream
pathways; for example, the PI3K/Akt pathway that leads to inhibition of cell death [104]. Despite the
efforts to alleviate the effects of growth factor receptors by targeted therapies against it, such therapies
are inadequate because of the rapid development of resistance. The use of HDACIs to control the
expression of growth factor receptors appears to be a promising approach; accordingly, in breast
cancer dacinostat, an HDACI disrupted EGF-mediated signaling that is linked to increased metastasis
and cell survival [105]. This effect was achieved by downregulating the expression ofHER2 (human
EGF-receptor-2) through two independent epigenetic mechanisms: by reducing HER2 mRNA level, and
by increasing proteasomal degradation due to dissociation from its chaperone protein HSP90 through
enhanced acetylation. Additionally, a combination of HDACI entinostat and Her2/EGF-receptor kinase
inhibitor, lapatinib synergistically inhibited Akt signaling to promote apoptosis in HER2-overexpressing
breast cancer cells [106].
HDACIs can also disrupt pro-survival signaling by enhancing apoptosis signaling pathways.
The binding of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to its receptors
death domain-containing receptor (DR) initiates pro-death signaling receptor expression stimulating
apoptosis through caspase cascade [107]. Cancer cells are frequently resistant to apoptosis due to
reduced DR receptor expression. These cells can be sensitized to overcome resistance to undergo cell
death by treating them with HDACIs. Exposure of breast cancer cells to vorinostat sensitized the
cancer cells to TRAIL-induced apoptosis by upregulating DR5 receptor expression [108,109].
Additionally, HDACIs can also sensitize cancer cells to overcome their dysregulated cell
cycle control and diminished activities of DNA damage repair pathways through their ability to
reverse dysregulated gene expression. Entinostat, an HDACI can sensitize breast cancer cells to
doxorubicin-induced growth arrest by downregulating the expression of myc, E2F, and other G2M
cell cycle genes. [75]. Entinostat in combination with decitabine, a DNA methyltransferase inhibitor,
is able to restore cell cycle control in pancreatic cancer through upregulation of p21 [75].
4.4. Mechanisms of Resistance to HDACIs
Cancer cells are highly resilient and adaptable in their ability to respond and to evade growth
inhibitory and toxic factors to survive and resist death. They constantly adjusting to overcome
the effects of damaging agents and environmental constraints to exist independently free from the
influence of external proliferative/survival stimuli. These acquired stable alterations may hinder cancer
cells response to the effects of HDACIs through developing different mechanisms to survive and
achieve resistance. A thorough understanding of molecular determinants of resistance to HDACIs
may provide the basis for therapeutic options with enhanced efficacy. Resistance to HDACIs is often
seen and involves different mechanisms [75,110,111]. Some of the resistance mechanisms to HDACIs
involves cell cycle proteins, thioredoxin expression, apoptosis-related proteins, signaling proteins,
and NF-kB expression.
Cell cycle proteins: It has been implicated that the induction of p21Cip1 in response to HDACIs is
responsible for cell cycle arrest and serves to play a protective role. Several studies have shown that
upregulated expression of p21Cip1 in response to HDACIs mediates cell cycle arrest and differentiation
or apoptosis [112]. When p21-deficient HCT116 cells are treated with romidepsin, cells get arrested in
the G2 phase compared to wild type cells [113]. The p21 is considered as a negative regulator of the cell
cycle and a cyclin-dependent kinase inhibitor implicated in apoptosis [114]. Studies in U937 leukemia
cells demonstrated that HDACI-induced p21Cip1 protected the cells from apoptosis, and blocking its
expression resulted in apoptosis [115].
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Thioredoxin expression: Resistance to HDACIs can be linked to an increased capacity of cancer
cells to resist oxidative stress. HDACIs increase ROS production and appear to be an important factor
in the proapoptotic effects of HDACIs. Increased expression of thioredoxins, peroxiredoxins, and redox
proteins that protect cells from ROS may acquire resistance to HDACIs. Treatment of cancer cells with
HDACIs causes oxidative stress by increasing ROS levels [116]. Cell death induced by HDACIs can be
partially rescued by preincubating with free radical scavenging N-acetylcysteine.
Apoptosis-related proteins: Increased expression of antiapoptotic proteins has been shown
to prevent HDACIs-mediated cell death. Increased levels of Bcl-2 and Bcl-x cause resistance to
the treatment of vorinostat, dacinostat, panobinostat, or oxamflatin [117,118]. The knockdown
of proapoptotic Bax in panobinostat-sensitive T-cell lymphoma cell lines resulted in diminished
toxicity [119]. On the other hand, knockdown of antiapoptotic Mcl-1 enhances HDACI-mediated
apoptosis in primary chronic lymphocytic leukemia cells and K562 cells [120]. These reports indicate
silencing of proapoptotic proteins blunts HDACIs-induced cell death.
Signaling proteins: Resistance to HDACIs is significantly associated with activation of PI3K and
MAPK pathways. A combination of panobinostat with compounds that abolish PI3K and MAPK
signaling result in synergistic cytotoxicity may be due to increased ROS [121]. A combination of
romidepsin with inhibitors of Akt resulted in synergistic cytotoxicity indicating phosphorylated Akt is
an important resistance mechanism to romidepsin. These and other combination studies targeting
different signaling molecules appear to cause resistance. Signal transducer and activator of transcription
(STAT) pathway also contributes to resistance to HDACIs. In a group of almost 40 lymphoma cell
lines, activation and expression of STAT-1, -3 and -5 was higher in cell lines that were more resistant to
vorinostat than in sensitive cell lines [122]. Analysis of a series of skin biopsy for the nuclear staining
of phosphorylated STAT3 recognized that patients with strong staining were more likely resistant to
vorinostat resistance [122]. The combination treatment with vorinostat and compounds that target
phosphorylated STAT3 may increase the efficacy.
NF-kB activation: The activation of the NF-kB pathway occurs in a number of cancers and leads to
the deactivation of the apoptotic pathway and increased cell survival [123]. It has been identified as a
mediator of resistance to HDACI treatment. Inhibition of HDAC by HDACIs enhances transcriptional
activation of NF-kB through acetylation of RelA/p65 subunit leading to the induction of an array of
genes involved in protection against cell death [124]. The activation of NF-kB by HDACIs interferes
with the triggering of cell death. In non-small lung cancer cell lines and leukemia cells, activation
of NF-kB by HDACIs triggers cell death [125,126]. Inhibition of NF-kB by its inhibitor Bay-11-7085
sensitizes the cancer cells to death in response to inhibition of HDAC.
Additionally, HDACIs can also sensitize cancer cells to overcome their dysregulated cell
cycle control and diminished activities of DNA damage repair pathways through their ability to
reverse dysregulated gene expression. Entinostat, an HDACI can sensitize breast cancer cells to
doxorubicin-induced growth arrest by downregulating the expression of myc, E2F and other G2M cell
cycle genes. [75]. Entinostat in combination with decitabine, a DNA methyltransferase inhibitor, is able
to restore cell cycle control in pancreatic cancer through upregulation of p21 [75].
5. Therapeutic Strategies
In cancer, genetic, epigenetic, and metabolic factors all participate in neoplasia by altering the
molecular networks that control cell proliferation, growth, differentiation, migration, and cell death.
Deregulation/misregulation of different molecular networks and misunderstanding in cross-talks
between epigenetic and non-epigenetic players that are linked to various cellular processes play
important role in the etiology of cancer. Supporting these effects, the aberrant expressions of HDACs
promote altered epigenetic modifications that endorse abnormal gene expression profiles [72–74,127].
The knockdown of several HDACs in some of these cancer cells stimulated cell cycle arrest and apoptosis
supporting the aberrant expression of HDAC activity is linked to cancer [97]. Relevantly, HDACIs
have a range of anticancer activities through the collaboration of their primary chromatin-associated

Int. J. Mol. Sci. 2020, 21, 8198

10 of 27

effects on gene transcription and their cellular effects [68,128]. These features of HDACIs supports
targeting epigenetic aberrations to prevent carcinogenesis, and open opportunities for HDACIs as the
class of anticancer agents. Several of these HDACIs have already been approved by the US FDA for
cancer treatment [see Section 4.1] and are in preclinical and clinical testing.
Although the HDACIs, when used as single agents, display potent anticancer activities on
hematological malignancies, they exhibit limited effectiveness in the suppression of solid tumors in
monotherapies [101,129]. The single HDAC therapeutic approach is frequently ineffective in providing
sustained tumor suppression because cancer cells can dodge drug-induced effect due to pharmacological
resistance, and also because of the toxicity and off-target effects of epi-drugs [130–133]. This letdown
has encouraged new drug design and therapeutic approaches to provide lasting tumor suppression.
The goal of drug discovery in the epi-drug research is no longer just the design of highly potent
and selective drugs acting on a specific epi-target, but advancing towards designing network-active
compounds with multitargeting capability through a polypharmacology approach [14–16,131–134].
5.1. Alternate Strategies Using Network-Active Compounds
The objective of the polypharmacology approach is to simultaneously hit all different targets
linked to the onset and development of a particularly complex disease at different levels so that
improved therapeutic effect is achieved [14–16,131–134]. The goal is to achieve a synergistic effect
by hitting a cellular pathway at different levels by using multitarget drugs. Synergistic therapeutic
effects can be achieved by three alternative strategies even though they exhibit striking differences.
These include multi-medication therapy (MMT, drug combination), multi-compound medication
(MCM, co-formulation of multiple active compounds), and multitarget-directed ligands (MTDLs,
single multitargeting compounds) [15,16]. Both MMT and MCM strategies have their own specific
targets but are based on the combination or association of two or more active principles, whereas
MTDLs strategy is designed to create a single molecule with an ability to simultaneously interact
with different targets. Specifically, a combination of epi-drugs with other anticancer agents including
kinase inhibitors, chemotherapeutic agents, hormonal inhibitors, and other epi-drugs for which
a rationale has been defined to benefit from synergistic effects of drug combinations have been
designed [15,16,131–134]. Some of them are under preclinical and clinical testing. Importantly, among
the several hybrid drugs produced, CUDC-907 is a promising orally bioavailable small-molecule
dual HDAC-PI3K inhibitor [15,16,134–144]. CUDC-907 simultaneously inhibits HDACs and PI3K
causing a synergistic effect. It is designed by introducing hydroxamic acid moiety as the zinc
binding functional group to a morpholinothienopyrimidine-based PI3K pharmacophore through
an appropriate linker [135]. Recently, another dual HDAC-PI3K hybrid drug is reported, which
is designed by introducing hydroxamic acid moiety as the zinc binding functional group to a
quinazoline-based PI3K pharmacophore through an applicable linker [143]. Different therapeutic
approaches involving HDAC-specific epi-drugs and PI3KIs directed against neoplastic diseases are
narrated in the following section.
5.1.1. HDACs-Specific Epi-Drugs Targeting HDACs
HDACIs induce multiple cellular effects specific to cell types through the mobilization of various
molecular pathways. Among these, the PI3K pathway is the most prominent pathway affected
by HDACIs. Since, dysregulation of PI3Ks and their downstream effector molecules forming the
PI3K/Akt/mTOR axis contribute to cancer initiation, progression, and growth, HDACIs are used as
single drugs to test whether their anticancer effect involves inhibition of PI3Ks in different cancer
cells and in animal xenograft cancer models. Moreover, determining the efficacy of single drugs is a
prerequisite for designing a multidrug combinational approach.
Sodium butyrate, an HDACI, inhibits cell proliferation, induces differentiation, or promotes
apoptosis in a variety of tumor cells. Gastric BGC823 cells treated with butyrate resulted in inhibition
of cell proliferation, altered cellular morphology, and increased expression of PTEN and mucosal factor
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MUC2, but decreased expression of PI3K [145]. These effects are heightened by intervention with PI3K
inhibitors and lessened with PTEN siRNA indicating sodium butyrate induced upregulation of PTEN
and MUC2 expression and differentiation of gastric cancer cells are mediated through the PTEN/PI3K
signaling pathway [145].
Esophageal squamous cell carcinoma (ESCC) is a highly malignant and lethal disease. Treatment
of ESCC cells with Trichostatin A (TSA), an HDACI, inhibited proliferation of ESCC cells and arrested
the cells in the G1 phase by upregulating p21Cip1 and p27Kip1 cell cycle inhibitors [146]. TSA also
induced apoptosis by upregulating pro-apoptotic protein Bax and downregulating anti-apoptotic
Bcl-2.
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Panobinostat, approved for the treatment of multiple myeloma patients, was tested for its efficacy
Panobinostat, approved for the treatment of multiple myeloma patients, was tested for its
on NB4 cells and primary acute promyelocytic leukemia (APL) patient cells. The results indicate
efficacy on NB4 cells and primary acute promyelocytic leukemia (APL) patient cells. The results
panobinostat not only effectively reduces the survival rate of both NB4 and APL primary cells, but also
indicate panobinostat not only effectively reduces the survival rate of both NB4 and APL primary
eliminated the stimulatory survival effect of microenvironment signals transduced by mesenchymal
cells, but also eliminated the stimulatory survival effect of microenvironment signals transduced by
stem cells (MSC) on APL cells by incorporating PI3K inhibitor when APL cells are co-cultured with
mesenchymal stem cells (MSC) on APL cells by incorporating PI3K inhibitor when APL cells are coMSC [147].
cultured with MSC [147].
Romidepsin (depsipeptide, FK228) approved for the treatment of cutaneous and peripheral T-cell
Romidepsin (depsipeptide, FK228) approved for the treatment of cutaneous and peripheral Tlymphoma treatment directly inhibits PI3K activity and strongly promotes apoptosis through its
cell lymphoma treatment directly inhibits PI3K activity and strongly promotes apoptosis through its
HDAC/PI3K dual inhibition [148]. Furthermore, FK-A11, an analog of depsipeptide, is reported to be
HDAC/PI3K dual inhibition [148]. Furthermore, FK-A11, an analog of depsipeptide, is reported to be
the most potent HDAC/PI3K dual inhibitor exhibiting antitumor activity in HT1080 fibrosarcoma and
the most potent HDAC/PI3K dual inhibitor exhibiting antitumor activity in HT1080 fibrosarcoma
PC3 prostate cancer cell xenograft mouse models [149].
and PC3 prostate cancer cell xenograft mouse models [149].
Vorinostat (SAHA, Zolinza) is a good efficacious, well-tolerated drug that has been used in the
Vorinostat (SAHA, Zolinza) is a good efficacious, well-tolerated drug that has been used in the
treatment against CTCL. It also exhibits anti-solid tumor effects for other types of cancer in monotherapy
treatment against CTCL. It also exhibits anti-solid tumor effects for other types of cancer in
and also in combination therapy. To understand the mechanism of Vorinostat anti-solid tumor activity,
monotherapy and also in combination therapy. To understand the mechanism of Vorinostat antiits effects on cervical cancer were investigated [150]. The outcome of these studies revealed that
solid tumor activity, its effects on cervical cancer were investigated [150]. The outcome of these
Vorinostat inhibits cell proliferation, migration, and invasion of cervical cancer cells, arrest cells in S
studies revealed that Vorinostat inhibits cell proliferation, migration, and invasion of cervical cancer
cells, arrest cells in S phase, and induces apoptosis. Furthermore, Vorinostat inhibited PI3K (p110α),
p-PI3K p55, and p-Akt protein expression and upregulated major histocompatibility class I-related
chain A (MICA) expression in vitro and in vivo, which promoted natural killer (NK) cell-mediated
cervical cancer cell lysis. These studies indicate that vorinostat exhibits anti-solid tumor activity by
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phase, and induces apoptosis. Furthermore, Vorinostat inhibited PI3K (p110α), p-PI3K p55, and p-Akt
protein expression and upregulated major histocompatibility class I-related chain A (MICA) expression
in vitro and in vivo, which promoted natural killer (NK) cell-mediated cervical cancer cell lysis. These
studies indicate that vorinostat exhibits anti-solid tumor activity by upregulating MICA expression in
cervical cancer cells through the mediation of the PI3K/Akt pathway, which enhances the susceptibility
of cervical cancer cells for NK cell-mediated cytolysis.
5.1.2. Multi-Drug Combination Targeting HDACs Activity and PI3K Pathway
Simultaneous
of two or more single-target inhibitors that are previously validated as effective
Int. J. Mol.
Sci. 2020, 21, use
x
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Recent evidence indicates frequent mutation in histone modifying proteins and dysregulation
of PI3K pathway in non-Hodgkin lymphoma (NHL), particularly in diffuse large B-cell lymphoma
(DLBCL). This observation prompted exploration of the effectiveness and an assessment of the
mechanisms of action of co-administration of panobinostat and BEZ235 in DLBCL cells [152].
Panobinostat and BEZ235 interact synergistically in ABC-, GC-, and double-hit DLBCL, but not in
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Recent evidence indicates frequent mutation in histone modifying proteins and dysregulation
of PI3K pathway in non-Hodgkin lymphoma (NHL), particularly in diffuse large B-cell lymphoma
(DLBCL). This observation prompted exploration of the effectiveness and an assessment of the
mechanisms of action of co-administration of panobinostat and BEZ235 in DLBCL cells [152].
Panobinostat and BEZ235 interact synergistically in ABC-, GC-, and double-hit DLBCL, but not in
normal CD34+ cells. The synergistic effect of panobinostat and BEZ325 was displayed by significant Akt
dephosphorylation and GSK3 dephosphorylation/activation. Drug combination promoted apoptosis as
revealed by abrogation of p21Cip1 induction, Mcl-1 downregulation, Bim upregulation, and increased
Bcl2/Bcl-xl binding and reduced Bax/Bak binding to Bcl/Bcl-xl/Mcl-1. Additionally, co-administration
of panobinostat and BEZ325 increased H2A.X phosphorylation and histoneH3/H4 acetylation. These
effects were collectively linked to the synergism of panobinostat and BEZ235. The synergistic
effect of a combination of panobinostat and BEZ235 underscores the therapeutic potential of a drug
combinational approach.
Sodium butyrate exhibited inhibitory effects on an aggressive metastatic human colon cancer cell
line, KM20 [153]. Sodium butyrate-mediated effect on these cells was enhanced by the inhibition of
the PI3K pathway resulting in apoptosis and reduced viability of KM20 cells. Co-incubation of KM20
cells with butyrate and PI3K inhibitor LY294002 or wortmannin enhanced colon cancer cell apoptosis
by activating caspase 9 and caspase 3. This finding indicates the anticancer effect of HDACI can be
synergized with a PI3KI, and effective in colon cancer treatment.
In tumorigenic non-small cell lung cancer, (NSCLC) resistance to HDACIs is mediated through
the activation of nuclear factor-kB (NF-kB) via PI3K/Akt-dependent pathway. Whether inhibition
of the PI3K/Akt pathway will allow the NSCLC cells to overcome the resistance to HDACI-induced
apoptosis was investigated using butyrate [154]. Treatment of NSCLC cell lines with butyrate
activated NF-kB-dependent transcription and this effect was inhibited by LY294002, a PI3KI. Combined
treatment of NSCLC with butyrate and LY294002 increased apoptosis by increasing caspase-3 level
and DNA fragmentation. In vivo, combined treatment of butyrate and LY294002 was tumoristatic
with decreased tumor growth and increased apoptosis. Decreased phospho-Akt level and increased
acetylated histone H3 level in tumor tissues treated with butyrate and LY294002 indicating NSCLC
xenografts can be sensitized to undergo apoptosis with combined treatment with HDACI and PI3K/Akt
pathway inhibitors.
Another study supports the superior efficiency of HDACI and BEZ235 combination treatment
against NSCLC [155]. Heightened activities of HDACs and PI3K/Akt signaling pathways have been
associated with NSCLC development and progression. Co-treatment of NSCLC cells with TSA and
BEZ235 reveals a synergistic effect on the inhibition of NSCLC cell proliferation and stimulation
of apoptosis. This combination also synergistically inhibited NSCLC migration, invasion, and the
NSCLC epithelial-mesenchymal transition in vitro. Furthermore, reduction in xenograft growth and
metastasis rates and ki-67 protein expression in vivo in response to co-treatment with TSA and BEZ235
also provides evidence for synergistic efficacy of the co-treatment, warranting further evaluation of
combination treatment approach for NSCLC.
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the
developed world. Despite improved surgical and radiological treatment of HNSCC, it continues to
be a serious disease and needs new treatment approaches. This situation brings HDACIs into the
picture for the treatment option. Studies have revealed that a variety of HDACIs exhibit anticancer
effects on squamous cell carcinoma (SCC) in vitro and in recent patient trials. However, the patient
trials have shown that HDACIs have limited therapeutic potential in monotherapies for the treatment
of HNSCC [156]. Since it is possible to boost anticancer effects of HDACIs by selective targeting of
the PI3K/Akt pathway, the effect of PI3K, Akt, and dual PI3K/mTOR inhibitors either alone or in
combination on the therapeutic potential of HDACIs in HNSCC cell lines and xenograft HNSCC
models was investigated [157]. Treatment of HNSCC cell lines with PI3K, Akt, and dual PI3K/mTOR
inhibitors demonstrate increased in vitro cytotoxicity induced by HDACIs. Furthermore, HDACIs
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and PI3KIs inhibited tumor growth of HNSCC xenograft models. In agreement with this effect,
intra-tumoral HDAC and PI3K inhibition was observed as evaluated by histone H3 acetylation status
and phospho-Akt staining, respectively.
Glioblastoma multiforme (GBM) is a common malignant brain tumor. GBM cells treated with
Panobinostat and BEZ235 alone or in combination were assessed for cell viability, proliferation, and
apoptosis, and mechanisms of cytotoxicity were evaluated [158]. The combination approach with
HDACI and PI3KI synergistically inhibited cell viability, significantly inhibited cell proliferation, and
stimulated apoptosis. Additionally, co-treatment also increased caspase 3/7 activity, suppressed markers
of cell proliferation and anti-apoptotic markers, and Akt signaling. These effects of a combination
approach with HDACI and PI3K/mTOR inhibitor are promising and necessitate further evaluation in
GBM therapy.
Medulloblastoma (MB) is a common malignant pediatric brain tumor. Based on genetic studies
there are four different molecular groups of MB. The most aggressive MB among these groups exhibits
amplification or overexpression of myc oncogene. Patients with myc-driven MB reveal poor prognosis
and need more effective treatment. Using an animal model of myc-driven MB, the effectiveness of
HDACIs was tested for their ability to decrease the viability of tumor cells [159]. HDACIs not only
potently inhibit the survival of myc-driven MB cells in vitro partly due to the upregulation of the
FOXO1 tumor suppressor gene, but also synergize inhibition of tumor growth in vivo in combination
with PI3KIs. These effects recognize the effectiveness of combination therapy for the most aggressive
form of MB.
5.1.3. Polypharmacology-Based Approach Targeting HDAC Activity and PI3K Pathway
While the traditional multi-drug combination therapy approach is based on a combination of two
or more drugs, each with its own specific target, the polypharmacology approach is designed to develop
a single-hybrid drug to simultaneously interact with multitargets that are responsible for the onset of a
disease. The hybrid drugs are created by conjugating two or more active molecules that individually
exhibit a confirmed activity against specific targets. Such a multitarget hybrid drug strategy has
been used to develop a dual HDAC-PI3K inhibitor hybrid drug that simultaneously inhibits HDACs
and PI3K pathway in cancer cells. Prior to developing the multitarget hybrid drug, to confirm the
potential synergistic response of HDAC and PI3K inhibition, individual effects of HDACI vorinostat
(SAHA) and PI3K inhibitor pictilisib (GDC-0941) on growth inhibition of human PC-3 prostate cancer
cells were determined [135]. Then the combined effect of vorinostat and pictilisib was compared to
their individual effect and analyzed using the median effect analysis [160]. The analysis indicated
significant combination index that was less than 1, which provided a rationale for the development of
a single dual HDAC and PI3KI hybrid drug. Based on this information, multitarget inhibitors were
designed and synthesized by integrating HDAC inhibitory hydroxamic acid functionality (vorinostat,
panobinostat, JNJ-16241199) into a core structure of morpholinothienopyrimidine pharmacophore
that is shared by several PI3KIs such as apitolisib (GDC-0980), pictilisib (GDC-0941), PI-103 and
BKM120 (Buparlisib [135]. One of these hybrid drugs identified is CUDC-907 (Figure 4). It was tested
to confirm whether it displays potent pan-inhibitor activity against HDAC class I and II enzymes,
and pan-inhibition against class I PI3Ks. Its potency against class I HDAC was found to be like that of
panobinostat and greater than vorinostat [135]. Similarly, CUDC-907 revealed potent inhibition of class
I PI3Ks with an IC50 of 19, 54, and 39 nmol/L for PI3Kα, P13Kβ, and PI3Kδ, respectively. This activity
is comparable to that of known PI3KI pictilisib (GDC-0941) [135]. CUDC-907 through its integrated
HDAC inhibitory activity induces lasting inhibition of PI3K-Akt-mTOR pathway and compensatory
signaling molecules such as Raf, MEK, MAPK, and STAT-3, and upstream receptor tyrosine kinases
as assessed by western blotting. Dose-dependent sustained downregulated phosphorylation of Akt
and its downstream targets, 4EBP-1, and p70S by CUDC-907 in H460 cells not only confirms the PI3K
pathway inhibitory activity of CUDC-907 but also exhibits the potential to evade resistance stemming
from downstream activation of Akt. CUDC-907 also induced the accumulation of acetylated histone
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H3, tubulin, and p53, the effects specific to HDAC inhibition. CUDC-907 displayed greater growth
inhibition and proapoptotic activity than single-target HDAC and PI3K inhibitors in both cultured
and implanted cancer cells of xenograft tissue. Taken together, CUDC-907 evades drug resistance,
stimulates
Int. J. Mol. Sci.apoptosis,
2020, 21, x and induces cell cycle arrest.
15 of 27
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activation of ERK1/2 considering their role in cell proliferation. This response may represent
resistance to CUDC-907. Furthermore, an assessment of the molecular mechanism linked to the
antitumor activity of CUDC-907 demonstrates that it involves induction of apoptosis and DNA
damage. CUDC-907 treatment-induced decreased antiapoptotic Mcl-1 and Bcl-xL levels, increased
proapoptotic Bim and decreased c-myc contribute to the onset of apoptosis. CUDC-907 also induced

CUDC-907 resulted in significant inhibition of tumor growth encouraging further clinical
development of CUDC-907 for prostate cancer treatment [144].
Upregulation of class I HDACs is a common feature in hepatocellular carcinoma (HCC), which
sponsors spreading, aggressiveness, and increased mortality. Motivated by the efficacious activity of
CUDC-907, efforts were made to design novel HDAC/PI3K dual hybrid drugs via bio-isosterism, by
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Figure 5. Schematic display of antitumor activity of CUDC-907 hybrid drug against prostate cancer
cells. Synergistic anti-cancer activity of CUDC-907 is illustrated by its inhibition of HDACs activity
Figure 5. Schematic display of antitumor activity of CUDC-907 hybrid drug against prostate cancer
and PI3K/Akt pathway [144]. Increase in histone 4 acetylation and reduced activation of PI3K/Akt
cells. Synergistic anti-cancer activity of CUDC-907 is illustrated by its inhibition of HDACs activity
confirms its dual action on HDAC and PI3K. Outcome of these effects resulted in inhibition of cell
and PI3K/Akt pathway [144]. Increase in histone 4 acetylation and reduced activation of PI3K/Akt
proliferation, increase in DNA damage due to downregulation of DNA damage repair response proteins,
confirms its dual action on HDAC and PI3K. Outcome of these effects resulted in inhibition of cell
and apoptosis because of downregulation of c-myc and antiapoptotic Mcl-1 and Bcl-xL proteins, and
proliferation, increase in DNA damage due to downregulation of DNA damage repair response
upregulation of pro-apoptosis protein Bim (blunt end lines indicate inhibition, upward arrows indicate
proteins, and apoptosis because of downregulation of c-myc and antiapoptotic Mcl-1 and Bcl-xL
upregulation and downward arrows indicate downregulation of proteins).
proteins, and upregulation of pro-apoptosis protein Bim (blunt end lines indicate inhibition, upward
arrows indicate upregulation and downward arrows indicate downregulation of proteins).

Upregulation of class I HDACs is a common feature in hepatocellular carcinoma (HCC), which
sponsors spreading, aggressiveness, and increased mortality. Motivated by the efficacious activity
of CUDC-907, efforts were made to design novel HDAC/PI3K dual hybrid drugs via bio-isosterism,
by replacing morpholinothienopyrimidine moiety (Figure 6A) in CUDC-907 with a morpholinopurine
(Figure 6B,C) [137]. All compounds generated displayed strong anti-HDAC1 and anti-PI3Kα
activities. CUDC-907 exhibited IC50 values of 1.7 and 19 nM for HDAC1 and PI3Kα, respectively
(Figure 6A). Among the several analogs obtained, the compounds having a pyrimidine (Figure 6B)
or aminopyrimidine (Figure 6C) at the C-2 position of the morpholinopurine moiety, demonstrated
expected dual PI3Kα and HDAC1 inhibitory activities. The IC50 values for the analog in Figure 6B
against HDAC1 and PI3Kα were 1.14 and 28.06 nM, respectively. Analog in Figure 6C displayed lower
and balanced IC50 values for HDAC1 and PI3Kα, 1.04, and 1.33 nM, respectively.
Using the polypharmacology-based paradigm, two other dual HDAC-PI3K inhibitors were
recently reported [143]. These inhibitors were designed by introducing hydroxamic acid moiety as the
zinc binding functional group to a quinazoline-based PI3K pharmacophore through an appropriate
linker. Nanomolar concentrations of both these lead inhibitors simultaneously inhibit PI3K and HDAC
activity. These inhibitors inhibited proliferation, arrested the cell cycle, and induced apoptosis of
HCT116 cancer cells. Furthermore, they also altered p-Akt expression and acetylated histone H3 in
HCT116. Pharmacokinetic studies in HCT116 and HGC-27 xenograft models further demonstrate
that they have significant anticancer efficacies. Taken together, this study further supports the dual
HDAC-PI3K hybrid drugs that have potential anticancer activity.
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outcome of complex multifactorial genetic and epigenetic alterations, drug combinations or single
multitarget hybrid drug molecules have a better opportunity to modify or reverse the altered disease-
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synergistic effects of the drug combination. As a result, the MMT approach can reduce the chances
of drug resistance and adverse reactions compared to single-drug treatment [15,16]. While the MMT
approach provides flexibility to choose different dosages and therapeutic schedules, it also causes
problems with patient compliance. The MCM approach can offset the negative impact on patient
compliance by providing multi-medications in the form of a co-formulated single tablet [16]. However,
both MMT and MCM approaches present several challenges. The use of drugs with very different
chemical structures in the same therapeutic drug combination complicates pharmacodynamic and
pharmacokinetic requirements. Other problems include drug–drug interactions and potential solubility
issues of the active substances that can modify the bloodstream uptake. Similarly, the simultaneous
presence of drugs in the target tissues is not guaranteed to promote a synergistic response. Additional
complications include each tumor and the therapeutic response of each patient is different.
Unlike drug combination approaches, the use of single multitarget hybrid drugs created based on
the multitarget-directed ligands (MTDLs) approach exhibits promising outcomes for solid tumors and
drug-resistant cancers. The single multitarget hybrid drugs created by using the polypharmacology
principle can simultaneously hit two or more targets. Importantly, single multitarget hybrid drugs
have several advantages over the drug combinations. They display better pharmacokinetics and
pharmacodynamics such as no solubility/bioavailability issues, greater therapeutic efficacy, lower
toxicities, the simultaneous presence of the chemical entities in multiple tissues, and improved patient
compliance [15,16]. Specifically, single multitarget hybrid drugs that can simultaneously hit two or
more targets in which one (or more) is (are) epigenetic and the other (s) belongs to a non-epigenetic
category(ies) have greater potential for cancer therapy. This concept has resulted in the design and
development of multitarget epigenetic hybrid drugs. Among the several epigenetic hybrid drugs
produced, CUDC-907 is a promising single dual HDAC-PI3K inhibitor molecule with an ability
to simultaneously inhibit HDACs and PI3K [15,16,134–144]. CUDC- 907 is an orally bioavailable
small -molecule dual HDAC and PI3K inhibitor targeting class I and II HDACs and PI3Kα, β, and
δ isoforms [135]. Its extensive antitumor activities in hematologic and solid tumors show promise
as an HDAC-PI3K inhibitor [134–144]. Considering the pleiotropic effects of HDAC inhibition and
the multiple downstream effectors of PI3K, it is not surprising CUDC-907 has a better opportunity to
reverse the altered molecular pathways linked to oncogenesis. Even with the frequent difficulty in
structural optimization to effectively merge the pharmacophoric portions of HDAC and PI3K entities
to generate dual HDAC-PI3K inhibitor, it was possible to generate CUDC-907. Importantly, preclinical
findings indicate the use of CUDC-907 has several advantages over the drug combination treatment
with single-target HDAC and PI3K inhibitors (MMT and MCM) [15,16,135]. CUDC-907 exhibits
better pharmacokinetics and pharmacodynamics such as no solubility/bioavailability issues, greater
therapeutic efficacy, lower toxicities, the simultaneous presence of the chemical entities in multiple
tissues, and improved patient compliance [15,16,135]. Moreover, CUDC-907 is well tolerated with
manageable gastrointestinal and hematologic events compared to a combination of single HDAC and
PI3K inhibitors without any infections, hepatotoxicity, or cardiotoxicity [136]. Adjusting dosing is
simpler and pharmacokinetics and toxicity profiles are predictable. Based on these preclinical outcomes,
CUDC907 was entered into phase I study to determine the safety, tolerability, and pharmacokinetics in
patients with advanced/relapsed solid tumors (NCT02307240). Based on encouraging results from the
phase I study, a biomarker-driven phase II (NCT02674750) study has been initiated in patients with
myc mutation.
7. Conclusions and Perspectives
Epigenetic drug discovery is a rapidly evolving field, and the use of epigenetic drugs both in
clinical and preclinical trials forecast a promising future for the treatment of multifactorial diseases
such as cancer. The first dual inhibitor targeted at an epigenetic target was reported in 2007 and since
then several dual inhibitors aimed at epigenetic targets have been reported. Importantly, most of these
inhibitors include HDAC inhibition as one of their mechanisms of action. This is attributed to the
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high resilience offered by the HDAC pharmacophore. Moreover, the characteristics of HDACs and
strategies for their inhibition are better understood compared to other epigenetic targets. CUDC-907
is one of the successes of the combination of HDAC inhibition with PI3K inhibition. Several other
epigenetic drugs are undergoing clinical trials in combination with other therapeutic agents via linked
pharmacophores that can provide synergistic effects both for solid and hematologic cancers. CUDC-907
inhibits classical HDACs and all four class I PI3K isoforms in nanomolar amounts, and is currently
in phase II cancer trials. Despite the promising efficacy in hematologic cancers, there is still a poor
prognosis for solid tumors due to poor cancer-targeting specificity. A recent report indicates that a
nanoparticle-based pre-targeted delivery system improves the therapeutic window of small-molecule
inhibitors [161]. This approach increases the number of nanoparticles retained on the target tumor
cells, improves the drug delivery, and shows the antitumor activity of BEZ235 through the inhibition
of PI3K/mTOR. The use of nanoparticle-based drug delivery technology may improve the delivery of
CUDC-907 to target cancer tissues, and at the same time, normal tissues can be protected. The future
looks bright for dual inhibitors directed at epigenetic targets and their full potential in the treatment of
complex diseases is yet to be explored.
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